|
|
Article: Mercury Therapeutics Licenses Critical Oncology Target to Discover Lead Compounds.
- Article from:
- PR Newswire
- Article date:
- December 2, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WOBURN, Mass. -- Mercury Therapeutics, Inc. (MTI), a privately-held biopharmaceutical company, announced that it has recently acquired the exclusive, world-wide rights to a critical drug target in oncology from Massachusetts General Hospital. The technology will be used by the Company to develop small molecule inhibitors to the Ras-Raf protein interaction, a well validated but completely unexploited oncology drug target. "We are very pleased to have Mercury Therapeutics license the Ras-Raf technology. They have an excellent group of scientists coupled with a robust high throughput screening capability that will enable them to rapidly identify and develop inhibitors of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Critical oncology target licensed from Mass General.
Biotech Week;
January 29, 2003 ;
520 words
... ... com & NewsRx.net) -- Mercury Therapeutics, Inc., (MTI), a privately held biopharmaceutical company, announced that it has recently ... We are very pleased to have Mercury Therapeutics license the Ras-Raf technology ...
|
|